Unique Features
Implantable Cardiac Devices
Managed Ventricular Pacing
Clinical Need
MVP Promotes Intrinsic Conduction
A patient's risk of AF doubles with ventricular pacing (DDD-L or DDD-S) vs. atrial pacing (AAIR).1 Even with long AV delays, programmed DDD pacing leads to AF.1
In patients with sinus node dysfunction:
- When ventricular pacing is less than 40%, for each 10% increase in ventricular pacing there is a 54% relative increase in risk for heart failure hospitalization.2
- When ventricular pacing is greater than 40%, a patient's relative risk for heart failure hospitalization remains constant.2
- The risk of atrial fibrillation increases linearly as the percentage of ventricular pacing increases from 0% to 85%.2
Rise of Heart Failure Hospitalization Relative to Ventricular Pacing
Risk of Atrial Fibrillation Relative to Ventricular Pacing
Promoting Intrinsic Conduction Without Compromising Safety
Managed Ventricular Pacing (MVP®) is an atrial-based pacing mode that significantly reduces unnecessary right ventricular pacing 2,3 by primarily operating in an AAI(R) pacing mode while providing the safety of a dual chamber backup mode if necessary.
MVP Operation
References
1
Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL, Pederson AK. A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome. J Am Cardiol. August 20, 2003;42(4):614-623. Comment in J Am Coll Cardiol. 2003;42:624-626.
2
Sweeney M, Hellkamp A, Ellenbogen K, et al, for the MOde Selection Trial (MOST) Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.
3
Gillis AM et al, Reduction of unnecessary right ventricular pacing due to the managed ventricular pacing (MVP) mode in patients with symptomatic bradycardia: benefit for both sinus node disease and AV block indications. HRS. 2005 Abstract; AB21-1.